Conference Track

Resistance, New Agents, and Management of Antiretroviral-Experienced Patients

Source: CCO Independent Conference Coverage of the 2004 International AIDS Conference*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Confirmation of Resistance Mutations Observed in Patients Failing Enfuvirtide
Addition of Zidovudine/Lamivudine to Single-Dose Nevirapine Reduces Maternal NNRTI Resistance
Twice-Daily Fosamprenavir/Ritonavir and Lopinavir/Ritonavir Have Similar Efficacy in Patients With Protease Resistance Mutations
Preliminary Data Indicate D-d4FC to Be Potent and Well Tolerated in Treatment-Experienced Patients
Safety and Efficacy of Enfuvirtide Maintained at 2 Years
Novel CCR5 Antagonist, GW 873140, Has Significant In Vitro Activity Against Clinical and Laboratory Isolates of HIV
Identification of Novel Small-Molecule HIV-1 Fusion Inhibitors
Lamivudine Monotherapy Better Than Complete Treatment Interruption in Patients With M184V Mutation
Less Resistance in Infants Given Nevirapine for Postexposure Prophylaxis
Five Years of Lopinavir/Ritonavir Resistance Data Confirm Absence of Protease Inhibitor Resistance With First-line Therapy
Resistance Mutations Occur in Patients Despite Stable Low Levels of Viremia
Maintenance of CD4+ Cell Count Associated With Lower Viral Replication Capacity in Patients With Genotypic and Phenotypic Resistance
Impact of Enfuvirtide on Early Virologic and Immunologic Responses in Heavily Treatment-experienced Patients
Boosted Saquinavir Once Daily as Effective as Boosted Indinavir Twice Daily
UK-427,857, a Novel CCR5 Receptor Antagonist,Shows Promise in HIV-infected Subjects

Expert Analysis

Resistance, New Agents, and Management of Antiretroviral-Experienced Patients

Program Director: John P. Phair, MD

Faculty:

Daniel R. Kuritzkes, MD
William A. O'Brien, MD, MS
Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of recent clinical studies of antiretrovirals regimens for treatment-experienced patients
Describe novel antiretroviral agents currently in clinical studies
Review new findings regarding resistance to NRTIs

Earn CME credit by reading the expert analysis and commentary on resistance. Topics covered include:

Fosamprenavir/Ritonavir in PI-Experienced Patients
Resistance to Lopinavir/Ritonavir
Efficacy of Boosted Tipranavir
Management of Resistance to NRTIs
Genotypic Predictors of Response to Didanosine
Lamivudine Monotherapy vs Treatment Interruption
Longer-term Follow-up of Response to Enfuvirtide
Chemokine Receptor Antagonists
Resistance Issues in Prevention of Mother-to-Child Transmission

CREDIT INFORMATION

Release Date: August 19, 2004

Expiration Date: August 18, 2005

Physicians: maximum of 2.0 AMA PRA Category 1 Credits™

Registered Nurses: 2.6 Nursing contact hours

Pharmacists: 2.25 contact hours (0.23 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.